Full text is available at the source.
Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)
Improving Temozolomide chemotherapy by reducing DNA repair enzyme MGMT using CRISPR-dCas9
AI simplified
Abstract
A significant reduction in MGMT expression was observed, leading to heightened sensitivity to Temozolomide (TMZ) in the HEK293T cell line.
- MGMT is associated with resistance to the chemotherapy drug Temozolomide (TMZ) in glioblastoma.
- Selective downregulation of MGMT transcription was achieved using a CRISPR-based approach combining inactive Cas9 with DNA methyltransferases.
- Inducing methylation at the MGMT promoter and K-M enhancer resulted in decreased MGMT levels.
- The enhanced sensitivity to TMZ suggests a potential strategy to overcome drug resistance in glioblastoma cells.
AI simplified